Dundee spinout Exscientia has filed for an offering that would provide exits for SoftBank Vision Fund 2, Novo, BMS, Celgene, Evotec and Pivotal BioVenture Partners.

Exscientia, a UK-based drug discovery technology developer backed by several corporate investors, filed for an initial public offering in the US on Friday, using a customary $100m placeholder amount. The company has also secured a commitment from Bill and Melinda Gates Foundation to raise $35m in a concurrent private placement. Founded in 2012, Exscientia has…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.